Golimumab

Drug Profile

Golimumab

Alternative Names: Anti-TNF-alpha monoclonal antibody - Centocor/Medarex; CNTO-148; Shinponi; Simponi; Simponi Aria; Simponi I.V; Sympony; Symposony

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Centocor Ortho Biotech; Janssen Biotech; Janssen Pharmaceutical KK; Merck & Co; Mitsubishi Tanabe Pharma Corporation
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antirheumatics
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase I/II Hearing disorders
  • Phase I Type 1 diabetes mellitus
  • Discontinued Asthma; Cardiovascular disorders; Sarcoidosis; Uveitis

Most Recent Events

  • 04 Jul 2017 Launched for Juvenile rheumatoid arthritis (Combination therapy) in Norway (SC)
  • 14 Jun 2017 Additional efficacy data from a the phase III GO-ALIVE trial in Ankylosing spondylitis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 14 Jun 2017 Safety and efficacy data from the phase III GO-VIBRANT trial in Psoriatic arthritis released by Janssen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top